1H-indazole-3-carboxylic acid [2-(4-nitroanilino)-2-oxoethyl] ester is a complex organic compound with a specific chemical structure.
**Here's a breakdown of its components and their potential significance:**
* **1H-indazole-3-carboxylic acid:** This is the core structure of the molecule, containing an indazole ring system (a five-membered ring fused to a benzene ring) with a carboxylic acid group attached to the third carbon atom. Indazoles are known for their diverse biological activities, including anti-inflammatory, antibacterial, and anti-tumor effects.
* **[2-(4-nitroanilino)-2-oxoethyl] ester:** This part describes the ester group attached to the carboxylic acid. The ester group is formed by the reaction of the acid with a specific alcohol. In this case, the alcohol is a derivative of 4-nitroaniline, a compound that has been associated with anti-cancer activity.
**Potential Importance for Research:**
The combination of these features suggests that this compound could possess interesting properties for research, potentially in the areas of:
* **Medicinal Chemistry:** The indazole core and the nitroaniline derivative could contribute to the molecule's biological activity. The presence of an ester group can impact a molecule's absorption, distribution, metabolism, and excretion (ADME) properties, which are crucial for drug development.
* **Materials Science:** The specific structure might offer potential for use in materials design, perhaps as a building block for polymers or other functional materials.
**It's Important to Note:**
* **Lack of Information:** The name itself doesn't provide enough information to definitively state the compound's specific properties or research applications.
* **Further Research:** Detailed research, such as in-vitro and in-vivo studies, would be needed to determine the compound's actual biological activity, efficacy, toxicity, and potential therapeutic applications.
**To learn more about this specific compound, you would need to access specialized scientific databases or consult with researchers working in relevant fields.**
ID Source | ID |
---|---|
PubMed CID | 4296334 |
CHEMBL ID | 1307854 |
CHEBI ID | 120799 |
Synonym |
---|
HMS2575E07 |
OPREA1_807379 |
smr000259366 |
MLS000390102 |
CHEBI:120799 |
[2-(4-nitroanilino)-2-oxoethyl] 1h-indazole-3-carboxylate |
CHEMBL1307854 |
AB00569723-02 |
Q27208940 |
1h-indazole-3-carboxylic acid [2-(4-nitroanilino)-2-oxoethyl] ester |
Z18545064 |
AKOS033630562 |
Class | Description |
---|---|
indazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.7079 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 10.0000 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
TDP1 protein | Homo sapiens (human) | Potency | 7.3078 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 3.1623 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 15.8489 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 12.5893 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |